Search for: "CIPLA" Results 121 - 140 of 202
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
24 Jan 2007, 9:59 pm
  Teva filed suit against at least the following companies:  Cipla; Hetero Drugs; Zydus-Cadila Healthcare; Sandoz; Andrx; Genpharm; Invagen; Lupin; and Apotex. [read post]
12 Feb 2010, 6:55 am by Ashby Jones
“The U.S. would grant a patent to a piece of toilet paper,” says Amar Lulla, chief executive of Cipla, the Indian generics drugmaker. [read post]
24 Jul 2008, 2:48 am
The judge gave preliminary approval last week for the company to pay $13.5 million to settle the suit.Indian Drugmaker Openly Plans for Release of Copycats: Cipla Ltd, India's second largest drug maker by sales, may launch copycat versions of 20 patented drugs of leading global drug makers, after securing similar-sounding trademarks for its copy brands.Cipla "may launch these generic brands in the market as and when the opportunity arises", claimed a company executive, who… [read post]
3 Aug 2013, 6:35 am by Anubha Sinha
In another instance, when Big pharma threatened legal action against the South African government in the latter's efforts to bring down prices for HIV-AIDS treatment, Indian pharma major Cipla stepped in and offered to supply drugs at just $350 per patient per year. [read post]
14 Mar 2014, 3:22 am
Doors open at 6 pm and the screening is from 7.30 pm – 8.15 pm, followed by a question and answer session with Chairman of Cipla, Dr Yusuf Hamied. [read post]
31 Dec 2012, 11:41 pm by Shouvik Kumar Guha
Next in line is a guest post by Madhulika Vishwanathan in the Spicy IP Fellowship Post Series, wherein she has referred to few landmark judgments in 2012 pertaining to the Indian pharmaceutical patent industry, including the grant of compulsory license to Natco Pharma, revocation of the Sunitinib patent owned by Pfizer/Sugen, the Roche-Cipla patent infringement suit, revocation of India’s first pharmaceutical product patent etc. [read post]
28 Feb 2013, 5:11 pm by Madhulika Vishwanathan
In fact generics like Cipla have set up their plants in Africa and extending the transition period would attract investments from even more generic companies. [read post]
7 May 2021, 6:25 am by Badrinath Srinivasan
Murali Neelakantan - Principal Lawyer, Amicus and former Global General Counsel, Cipla Limited The panellists for Session I are: 1. [read post]
11 Feb 2013, 7:40 pm by Sai Vinod
Cipla for one continues to manufacture generic equivalents of Sorafenib despite a valid patent held by Bayer. [read post]
17 Apr 2009, 12:00 am
Ltd. sues 11 generics companies over Levaquin patents (Law 360) Lexapro (Escitalopram) – Netherlands District court invalidates Lundbeck’s patent EP ‘066 (IPKat) Lexapro (Escitalopram) - Baldwin’s rules explained (The SPC Blog) Lexapro (Escitalopram) – federal district Judge agrees to determine whether Forest Laboratories destroyed key documents (Law 360) Pegasys (PEG interferon alfa 2a) – Roche wins post grant opposition against Wockhardt… [read post]
14 Nov 2007, 8:59 pm
Ivax/Cipla Lotrel:  Novartis v. [read post]
21 Jan 2010, 1:00 am
UCB moves to the Delhi High Court against Cipla & IPO (Patentcircle) Argentina: custom confiscates counterfeit medicines (IP tango) India: Beejasurs of the Indian seed market (Spicy IP) IP Border measures concerning goods allegedly infringing Intellectual Property rights – article (IP tango)   Wisconsin Alumni Research Foundation (WARF) wins appeal in patent battle with Xenon (Technology Transfer Tactics), (IP Licensing Law) President Obama reportedly seeks to shorten… [read post]
8 Jul 2012, 9:30 pm by Darren
South African case law that has referred to European decisions that have caused the UKIPO to summarise the Principles as they have been referred to above include Adcock Ingram v Cipla Medpro (Sabel v Puma), Laugh it off Promotions v SAB (Canon v MGM), Puma v Global Warming (Marca Mode v Adidas) and Cowbell v ICS Holdings (Canon v MGM). [read post]
11 Jul 2009, 7:45 am by VC
., Cipla Ltd., Ranbaxy Ltd. and Hetero Drugs Ltd. and subsequently got rejected by the Chennai Patent Office on January 25, 2006. [read post]
5 Mar 2014, 12:01 pm by Ron Coleman
Anyway, I am grateful to IP diva-in-the-making Katherine Eppley of Pearne & Gordon for suggesting that CIPLA invite me to rock in Cleveland next Monday, whatever on earth that means (I mean “the rocking” — the “invitation” I made sure to get in writing). [read post]
10 Feb 2010, 4:47 pm
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/   Highlights this week included: India: Rejections from pre-grant appealable to IPAB by patent applicant: UCB Farchim SA v Cipla & Ors (Generic Pharmaceuticals and IP) (The Vanishing Point) (Indian Patent Oppositions) (Spicy IP) (Spicy IP) India: Nay patent linkages: Bayer v UOI upheld by Division Bench of Delhi High Court (Spicy IP) (Generic… [read post]
6 Feb 2009, 5:00 am
Stem cell research under Obama (Ars Technica) US: Oxford Gene Technology settles legal action with Bioarray Solutions over patents covering use of microassays for detection of DNA sequence variations (Patent Docs) US: BPAI affirms rejection of claims to an isolated protein over prior art disclosing nucleic acid encoding the protein: Ex parte Chuang (not precedential) (Patent Docs) (Post-Grant) US: Supreme petitioned to grant certiorari in two cases important to biotech patenting: In re Bilski and… [read post]
25 Jan 2008, 1:00 am
You can separately subscribe to the IP Thinktank Global week in Review at [feeds.feedburner.com]Highlights this week included:Chinese company Zhongyi Electronic sues Microsoft for alleged patent infringement relating to technology that converts Roman characters to Chinese characters: (Jurist), (China Hearsay), (IP Dragon),US Patent reform and surrounding controversy: general commentary and opinions: (Patent Baristas), (IPBiz), (IPBiz), (IPBiz), (Patent … [read post]
1 Apr 2013, 3:55 am by Prashant Reddy
The patent application had initially been rejected by the Controller of Patents in 2006, after hearing 5 pre-grant oppositions filed by various generic pharmaceutical companies including Ranbaxy, Cipla, Hetero and one patients group – the Cancer Patient Aid Association (CPAA). [read post]